Search academic texts

Information × Registration Number 0225U001193, (0123U100804) , R & D reports Title Determination of the effectiveness of specific and antiviral therapy for chronic hepatitis C in military personnel popup.stage_title Визначення ефективності специфічної та антивірусної терапії при хронічному гепатиті С у військовослужбовців Head Fedorchenko Serhii V., д.мед.н. Registration Date 27-01-2025 Organization State Institution "LV Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Sciences of Ukraine" popup.description1 to improve the treatment of patients with chronic viral hepatitis C with advanced fibrosis and cirrhosis of the liver with the aim of further prevention of liver fibrosis among military personnel popup.description2  Final research report: pages – 60, tables – 20, figures – 6, sources – 51. Object of the study – chronic viral hepatitis C. The aim of the work is to improve the treatment of patients with chronic viral hepatitis C with advanced fibrosis and cirrhosis of the liver in order to further prevent liver fibrosis in civilians and military personnel. Research methods – epidemiological, clinical, serological, biochemical, immunological, morphological, morphometric, statistical, informational. It was established that the use of direct-acting drugs (DADs) sofosbuvir + daclatasvir for the treatment of patients with chronic viral hepatitis C (CHC) who completed a course of antiviral therapy (ART) and had increased aminotransferase activity contributed to a decrease in the activity of liver enzymes and a decrease in laboratory manifestations of cytolytic syndrome. In the absence of comorbid pathology (diabetes mellitus and steatosis), the use of PPD allows to obtain a sustained virological response (SVR) after 12 weeks of treatment. With genotype 1b of the hepatitis C virus (HCV) and advanced stages of F3-F4 (Metavir) fibrosis, a sustained virological response was achieved in 96.6% of military personnel and 98.8% of civilian patients; with genotype 3a of HCV - in 92.5% of military personnel and 97.6% of civilians. It was determined that when using PPD for the treatment of patients with CHC, the fibrosis index significantly decreases from 0.72 ± 0.02 to 0.32 ± 0.04 (P < 0.05), which indicates the restoration of liver cells damaged by the virus, i.e., the regression of cirrhosis. It was found that the use of PPD for antiviral therapy of patients with CHC (civilians and military personnel) infected with HCV genotype 3a effectively reduces the fibrosis index and density of the liver parenchyma, prevents the progression of fibrotic changes and promotes their reverse development. In patients with CHC (including military personnel) compliant with PVT and pathogenetic therapy, with conc Product Description popup.authors Klymenko Zhanna B. Martynovych Tetiana L. Solianyk Iryna V. popup.nrat_date 2025-01-27 Close